Sunami, KazutakaKazutakaSunamiIkeda, TakashiTakashiIkedaSHANG-YI HUANGWang, Ming-ChungMing-ChungWangKoh, YoungilYoungilKohMin, Chang KiChang KiMinYeh, Su-PengSu-PengYehMatsumoto, MorioMorioMatsumotoUchiyama, MichihiroMichihiroUchiyamaIyama, SatoshiSatoshiIyamaShimazaki, ChihiroChihiroShimazakiLee, Jae HoonJae HoonLeeKim, KihyunKihyunKimKaneko, HitomiHitomiKanekoKim, Jin SeokJin SeokKimLin, Tung-LiangTung-LiangLinCampana, FrankFrankCampanaTada, KeisukeKeisukeTadaIida, ShinsukeShinsukeIidaSuzuki, KenshiKenshiSuzuki2023-06-072023-06-072022-082152-2650https://scholars.lib.ntu.edu.tw/handle/123456789/631868In the pivotal phase III, randomized, multicenter ICARIA-MM study (NCT02990338), isatuximab plus pomalidomide and dexamethasone (Isa-Pd) improved progression-free survival and overall response rate versus pomalidomide and dexamethasone (Pd) in the overall population of patients with relapsed/refractory multiple myeloma.enEfficacy and safety; Far East; Isa-Pd; Japan; RRMMIsatuximab-Pomalidomide-Dexamethasone Versus Pomalidomide-Dexamethasone in East Asian Patients With Relapsed/Refractory Multiple Myeloma: ICARIA-MM Subgroup Analysisjournal article10.1016/j.clml.2022.04.005356414092-s2.0-85131126183WOS:000834076800010